The present work investigates the relationship between cancer cell chemosensitivity and subcellular distribution, molecular interaction, and metabolism of an anticancer drug. To get insights into this relationship, we took advantage of the differential sensitivity of two breast cancer cell lines, MDA-MB-231 and MCF-7, to anthracyclines, along with the property of docosahexaenoic acid (DHA, 22:6n-3), to differentially enhance their cytotoxic activity. The fluorescent drug mitoxantrone (MTX) was used because of the possibility to study its subcellular accumulation by confocal spectral imaging (CSI). The use of CSI allowed us to obtain semiquantitative maps of four intracellular species: nuclear MTX bound to DNA, MTX oxidative metabolite in endoplasmic reticulum, cytosolic MTX, and finally, MTX in a low polarity environment characteristic of membranes. MDA-MB-231 cells were found to be more sensitive to MTX (IC 50 ‫؍‬ 18 nM) than MCF-7 cells (IC 50 ‫؍‬ 196 nM). According to fluorescence levels, the nuclear and cytosolic MTX content was higher in MCF-7 than in MDA-MB-231 cells, indicating that mechanisms other than nuclear MTX accumulation account for chemosensitivity. In the cytosol, the relative proportion of oxidized MTX was higher in MDA-MB-231 (60%) than in MCF-7 (7%) cells. DHA sensitized MDA-MB-231 (ϳ4-fold) but not MCF-7 cells to MTX and increased MTX accumulation by 1.5-fold in MDA-MB-231 cells only. The DHA-stimulated accumulation of MTX was attributed mainly to the oxidative metabolite. Antioxidant N-acetyl-L-cysteine inhibited the DHA effect on both metabolite accumulation and cell sensitization to MTX. We conclude that drug metabolism and compartmentalization are associated with cell chemosensitization, and the related cytotoxicity mechanisms may involve oxidative stress.
Experimental studies have shown that exogenous n-3 polyunsaturated fatty acids (PUFAs) may sensitize tumor cells to anticancer drugs, in cell culture or in animal tumors (Shao et al., 1995; Germain et al., 1999; Colas et al., 2004; Menendez et al., 2004 Menendez et al., , 2005 . These effects of n-3 PUFAs have been found to be inhibited by the presence of antioxidants (Germain et al., 1998; Colas et al., 2004 Colas et al., , 2005 Menendez et al., 2005) . Several mechanisms have been proposed to account for the effect of PUFAs in increasing anticancer drug efficacy. These include an increase in drug transport across the cell membrane (Burns and North, 1986; Spector and Burns, 1987) , generation of free oxygen radicals, and lipid peroxidation (Das, 1999; Rose and Connolly, 1999; Stoll, 2002) . Among the PUFAs, docosahexaenoic acid (DHA, a long-chain -3 polyunsaturated fatty acid) was the most potent in enhancing the cytotoxic effect of doxorubicin in the MDA-MB-231 breast cancer cell line (Germain et al., 1999) . Recently, we found that the DHA-induced increase in doxorubicin cytotoxicity was cell line-dependent and was linked to oxidative stress .
Mitoxantrone (MTX), an anthracenedione, has a spectrum of clinical activity similar to that of anthracyclines. The antineoplastic activity of anthracyclines and anthracenediones has been attributed mainly to topoisomerase II inhibition and to reactive oxygen species (ROS) production (Gewirtz, 1999) . However, MTX has been shown to generate free radicals to a much lesser degree than doxorubicin (Novak and Kharasch, 1985) . Little is known about the effect of DHA on the chemosensitivity of breast cancer cell lines to MTX. Supplementation of leukemia cells by DHA led to an increase in MTX uptake (Burns et al., 1988a) , but no change in the intracellular distribution of the drug was detected in subcellular fractions obtained by differential centrifugation and sucrose gradient separation after cellular disruption (Burns et al., 1988b) .
A direct way to study the intracellular accumulation of fluorescent MTX (Bell, 1988 ) is use of flow cytometry and fluorescence microscopy. High-resolution images of the intracellular distribution of MTX in various cell lines have been obtained with confocal fluorescence microscopy (Smith et al., 1992 (Smith et al., , 1997 Fox and Smith, 1995; Consoli et al., 1997; Kellner et al., 1997; Hazlehurst et al., 1999; Litman et al., 2000) . Nevertheless, band-pass analysis of the fluorescence intensity in confocal fluorescence microscopy limited the analysis to the overall drug detection and did not account for the fluorescence changes, depending on the drug environment/interaction.
An alternative to confocal fluorescence microscopy, the confocal spectral imaging (CSI) technique is based on measurement, at different points of a cell, of the fluorescence spectra, providing the ability to distinguish different molecular states of intracellular drugs (Sharonov et al., 1994) . CSI has been recognized as a potent tool for direct qualitative and quantitative study of MTX within compartments of living K562 cells (Feofanov et al., 1997a (Feofanov et al., ,b, 1999 . The main limitation of these CSI studies was a low sensitivity related to the use of the green light (514.5 nm) for excitation of red-absorbing MTX. As a consequence, the MTX concentrations used by Feofanov et al. during cell treatment had to be very high (5 to 10 M).
We have performed CSI scanning of MTX-treated MCF-7 and MDA-MB-231 cells by using resonance excitation with a red laser line (632.8 nm). Compared with the CSI method published previously (Feofanov et al., 1997a (Feofanov et al., ,b, 1999 , increased selectivity and sensitivity of intracellular MTX detection were achieved. The present CSI study better respects cellular physiology, through a reduction of cell exposure to both drug concentration (0.5 M) and laser radiation (30 W and 0.02 s/spectrum). Four intracellular species of MTX were thus identified and particular attention was paid to characterize the fluorescence of an oxidative metabolite of the drug.
We compared the intracellular distribution of the molecular species of MTX within two breast cancer cell lines, MCF-7 and MDA-MB-231, and examined the influence of DHA supplementation on this distribution. Our aim was to take advantage of the differential sensitivity of these two breast cancer cell lines to MTX and DHA to get insights into the mechanisms responsible for chemosensitization.
Materials and Methods
Drugs and Chemicals. Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich Chimie (Saint Quentin-Fallavier, France). Dilutions of mitoxantrone (Novantrone, 10 mg/5 ml; Sigma-Aldrich Chimie) were freshly prepared in Dulbecco's modified Eagle's medium (DMEM) containing 5% heat-inactivated fetal calf serum, 50 IU/ml penicillin, and 50 g/ml streptomycin (Cambrex, Gennevilliers, France) . N-Acetyl-L-cysteine (NAC) was used at 10 mM in DMEM medium. DHA (22:6n-3) methyl ester was used for this study. The fatty acid was dissolved in 99% ethanol and stored as stock solution (150 mM) under nitrogen at Ϫ80°C. For all experiments, fatty acid was prepared freshly from stock solution and diluted with growth culture medium (final ethanol concentration: 0.02%). ER-Tracker Green, rhodamine 123, and 5(and 6)-chloromethyl-2Ј,7Ј-dichlorodihydrofluorescein diacetate (CM-H 2 DCFDA) were purchased from Invitrogen (Cergy Pontoise, France).
Cell Culture. The human breast carcinoma cell lines MDA-MB-231 and MCF-7 were obtained from American Type Culture Collection (LGC Promochem, Molsheim, France). Cell lines were cultured in DMEM containing 5% heat-inactivated fetal calf serum, 50 IU/ml penicillin, and 50 g/ml streptomycin. Cells were cultured at 37°C in a humidified incubator with 5% CO 2 . The culture medium was changed each 24 h. Drug Cytotoxicity. Cells were seeded in standard 96-well plates (7 ϫ 10 3 cells/well). One day after seeding, the culture medium was changed and replaced by medium containing different concentration of MTX (10 Ϫ5 to 5 M) with or without DHA (30 M) during 7 days. Viability of cells were measured as a whole by the tetrazolium salt assay (Mosmann, 1983) . Cells were incubated at 37°C for 1 h with the tetrazolium salt (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) and metabolically active cells reduced the dye to purple formazan. Formazan crystals were dissolved with dimethyl sulfoxide. Absorbance was measured at 570 nm using a multiwell plate reader (SpectraMax 190 model; Molecular Devices, Sunnyvale, CA). Dose-response curves were plotted as percentages of the control cell absorbance, which was obtained from control wells (without MTX treatment). These values were fitted to a sigmoidal dose-response model (GraphPad Prism; GraphPad Software Inc, San Diego, CA): Y ϭ min ϩ (max Ϫ min)/(1 ϩ 10 log IC50 Ϫ X ), where Y is viability (as a percentage), X is log(MTX concentration, micromolar), min is minimum viability, max is maximum viability, and IC 50 is the concentration of MTX producing a 50% decrease of viability.
Instrumental Setup for CSI. Fluorescence measurements were carried out using a LabRam confocal microspectrometer (Horiba Jobin Yvon, Villeneuve d'Ascq, France) equipped with a low dispersion grating (300 grooves/mm) and with an automated X-Y-Z scanning stage. A color camera (Panasonic WV-CP454E) together with a VITEC video card provided a digitalized TV image of a sample illuminated with a white light source (phase-contrast optical view).
MTX fluorescence was excited with a 632.8 nm line of an internal, air-cooled, helium-neon laser. The power on the samples was ϳ30 W, the acquisition time was 0.02 or 0.05 s/spectrum. Particular attention was paid to normalizing the measured signal on acquisition time as well as on instrumental response, using a Si plate and a fluorescein solution as the intensity standard. Sample irradiation and collection of fluorescence were performed through a 100ϫ microscope objective (numerical aperture 0.90; Olympus, Tokyo, Japan). The confocal hole aperture was adjusted to 100 m to obtain ϳ0.8 m lateral and ϳ3.5 m axial resolution. The spectral resolution was 1 nm.
Performing CSI Mapping on Living Cells. The breast cancer cells (treated with or without DHA during 7 days) were incubated with MTX (0.5 M) for 1 h at 37°C and 5% CO 2 . When NAC (10 mM) was used, a preincubation (15 min) of the cells with NAC was performed before the incubation with MTX. Before CSI analysis, the medium containing drug was removed, and the cells were resuspended in fresh medium after two rinses with fresh medium (pH 7.4). A drop of this preparation was put on a microscope glass slide and covered with a thin coverslide. Isolated cells, selected for their apparently intact morphology, were analyzed individually.
To study the subcellular repartition of MTX, we used the two-dimensional mapping of an optical section at half-thickness of the cell. Cells were scanned within the x-y plane with a fixed step of 0.8 m that provided maps containing typically ϳ900 spectra (30 ϫ 30 points). The acquisition time was less than 2 to 3 min per entire cell map. Both acquisition and treatment of multispectral maps were performed with LabSpec software.
Generating Chemical Maps from Spectral Sets. Subcellular drug repartition was studied via analysis of both intensity and shape of fluorescence spectra within CSI maps, as described previously (Sharonov et al., 1994; Feofanov et al., 1997b) . Briefly, each experimental spectrum recorded in a confocal mode from a cell was fitted to a sum of four reference spectra of MTX taken with appropriate coefficients:
where F DNA , F cyt , F met , and F lp are the fluorescence spectra of, respectively, the MTX-DNA complex, the cytosolic complex of native MTX, the cytosolic complex of metabolized MTX, and MTX in a low polarity environment, referred to a unitary intensity (Fig. 1) . Each of these MTX species has a characteristic fluorescence spectral shape established by in vitro modeling. The values of C DNA , C cyt , C lp , and C met are spectral contribution factors of the respective drug species. These factors could be converted into concentrations, once the fluorescence yield of each of the above fluorophores will be known.
The fitting results were optimized with the least-squares method. The fitting error was Ͻ5% (typically 2-3%). The cellular autofluorescence was completely neglected, because of the absence of any significant fluorescence of the untreated cells under the conditions used.
The spectral contribution factors of each MTX species were used to generate the respective two-dimensional distribution map (thereafter referred to as a chemical map) over the cell. In this manner, four model-specific chemical maps were generated for each cell.
In view of significant cell-to-cell variations of the fluorescence intensity, each chemical map was brought to a relative intensity scale by normalizing all the spectra on the intensity of the most intense spectrum (typically that from Quantification of MTX Cellular Accumulation and Distribution. Two kinds of quantitative information were extracted from analysis of each mapaverage spectrum: First, fluorescence intensity (expressed in arbitrary units, thereafter called fluorescence level) in the spectral region between 645 and 935 nm was considered to be representative of overall intracellular MTX accumulation, and second, the average spectrum was fitted to a sum of four reference MTX spectra described above. The contribution factors obtained were interpreted as cell-average relative contents (fluorescence levels) of the specific drug species. The results were averaged over 16 to 23 cells for each kind of treatment.
Colocalization of MTX Oxidative Metabolite with Cellular Organelles. We labeled endoplasmic reticulum and mitochondria using two organellespecific fluorophores, ER-Tracker Green and rhodamine 123, respectively. MDA-MB-231 cells, treated for 1 h with 0.5 M MTX and washed in phosphate-buffered saline, were incubated for 20 min with 0.5 M ER-Tracker Green or 1 M rhodamine 123. Colocalization studies were performed using a 488 nm line of an Ar ϩ laser. The estimated laser power at the sample was ϳ20 W. The fluorescence spectra were recorded with an acquisition time of 1 s/spectrum. The CSI spectral maps were generated as described above.
Measurement of ROS. Cells were cultured in 9 cm 2 multiwell plates and treated with MTX at IC 50 during 7 days. Cells were washed twice with Hanks-Hepes solution (pH 7.3, 37°C) and then incubated during 30 min with 10 M CM-H 2 DCFDA in the dark at 37°C. CM-H 2 DCFDA is an indicator for reactive oxygen species (hydrogen peroxide and hydroxy and peroxyl radicals). Then, cells were washed twice with cold Hanks-Hepes (pH 7.3, 4°C) solution and sonicated in 1 ml of distilled water (4°C). Whole cells lysates were centrifuged (10,000g for 5 min at 4°C) and fluorescence intensities were measured on supernatants at 522 nm (excitation wavelength: 480 nm) with a Hitachi F-2500 spectrofluorimeter. For each supernatant, protein concentration was measured with BCA kit (Uptima; Interchim, Montluçon, France), and the normalized fluorescence (arbitrary units of fluorescence per milligram of protein) was calculated.
Statistics. Statistical analysis was carried out using Student's unpaired t test, one-way analysis of variance, and Newman-Keuls multiple comparison tests (GraphPad Prism); p Ͻ 0.05 was regarded as significant.
Results
MTX Cytotoxicity. Breast cancer cells were cultured for 7 days in a medium supplemented with MTX at concentrations ranging from 10 Ϫ5 to 5 M, without (control) or with 30 M DHA. DHA at 30 M was not toxic (trypan blue exclusion, data not shown).
In control conditions (absence of DHA), IC 50 concentrations of MTX were different in the two cell lines (18 Ϯ 6 nM for MDA-MB-231 and 196 Ϯ 70 nM for MCF-7). Figure 2 shows the corresponding dose-response curves. Supplementation of MCF-7 cells with DHA did not modify MTX cytotoxicity significantly: IC 50 ϭ 128 Ϯ 74 nM versus 196 Ϯ 70 nM in supplemented versus no supplemented cells, respectively ( p Ͼ 0.05). In contrast, in MDA-MB-231 cells, DHA supplementation led to an increase in MTX toxicity at concentrations between 10 Ϫ1 and 10 Ϫ3 M: IC 50 shifted from 18 Ϯ 6 to 4 Ϯ 1 nM. This 4.5-fold enhancement of MTX cytotoxicity by DHA was statistically significant ( p Ͻ 0.001). Cell viability experiments were also performed in the presence of the antioxidant NAC. Control or DHAsupplemented MDA-MB-231 cells were treated with MTX at several concentrations ranging from 10 to 40 nM in the presence of NAC. Addition of NAC (10 M for 7 days) suppressed the enhancing effect of DHA on cell sensitivity to MTX, as cell viability remained unchanged between control and DHA-supplemented cells upon treatment with MTX.
Overall Accumulation and Chemicals Maps of MTX Subcellular Distribution. The results on overall drug accumulation in the two cell lines are presented in Table 1 . In control conditions, the overall drug fluorescence level in MDA-MB-231 cells was 2.5-fold lower than that in MCF-7 cells. DHA supplementation led to a 1.5-fold increase in overall MTX accumulation ( p Ͻ 0.001) in MDA-MB-231 cells, whereas no significant change was observed in MCF-7 cells. At a single-cell level, the most intense fluorescence was found in nucleoli (intensity of 100%) and in nucleus (intensity of 50 -70%). The intensity observed in cytosol was between 20 and 40%. It was about 10% in the cell periphery (membrane).
Because of the possibility of spectral analysis of intracellular fluorescence inherent in the CSI approach, four specific maps characteristic of molecular environment/species of MTX were generated in each cell (Fig. 3A) . The maps of MTX-DNA fluorescence had nuclear localization. DHA treatment did not induce any change in these maps. Fluorescence of the MTX metabolite typically had a strong perinuclear spot and a weaker diffusion within the cytosol. The metabolite maps were larger and more intense in MDA-MB-231 than in MCF-7 cells. DHA supplementation resulted in a strong increase of the metabolite fluorescence in both cell lines. In contrast, this increase was inhibited in the cells treated with NAC antioxidant. The cytosolic complex of native MTX was distributed all over the cytosol. This staining was different in the two cell lines: homogeneous in MCF-7 cells and with multiple spot distribution in MDA-MB-231 cells. Supplementation with DHA led to a decrease in the level of the native MTX cytosolic complex, particularly in MDA-MB-231 cells. Maps of MTX in a low polarity environment fitted cellular contours (plasmic membranes) as well as several perinuclear spots (intracellular membranes). After DHA supplementation, this staining was reduced, mainly in intracellular membranes.
Colocalization of Specific Species of MTX. Deconvolutions of spectra from nuclear region corresponded to a 100% contribution of characteristic fluorescence assigned to MTX-DNA complexes. In contrast to the nuclear fluorescence, the spectra from other cellular regions were decomposed into variable contributions of two or three reference spectra, thus indicating colocalization of corresponding molecular species of MTX (Fig. 3B) . Spectra from the intense perinuclear regions were particularly mixed, as they corresponded to the spectrum of the cytosolic complex of native MTX enriched with the fluorescence of the complex of the metabolized MTX and complemented the spectrum characteristic of MTX in a low polarity environment (intracellular membranes). This finding is illustrated by the certain similarity of the respective maps seen in Fig. 3A , with all having bright spots in the perinuclear regions. The colocalization was confirmed after superposition of the respective maps encoded in pseudo-colors (Fig. 3B) 
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at ASPET Journals on July 7, 2017 dmd.aspetjournals.org white perinuclear spots correspond to a mixture of three colors, i.e., of three species, indicating that the cytosolic complex of metabolized MTX is located in perinuclear regions enriched with membranes.
To check a possible assignment of these regions to cellular organelles such as mitochondria or endoplasmic reticulum, we stained the MDA-MB-231 cells with rhodamine 123 and ER-Tracker Green, respectively. The excitation wavelength of 488 nm was used, because it was optimal for ER-Tracker Green and rhodamine 123 (emission maxima at 517 and 540 nm, respectively) and was still suitable to detect the MTX metabolite. According to the CSI data, the metabolite fluorescence was colocalized with the fluorescence of ER-Tracker Green (Fig. 4) but not with the fluorescence of rhodamine 123 (data not shown).
Cell-Average Intracellular Content of the Specific Species of MTX. Average fluorescence levels corresponding to the four specific species of MTX are shown in Fig. 5 . This figure provides quantitative evidence that the subcellular repartition of MTX is cell line-dependent.
The relative fraction of MTX bound to DNA was similar in both cell lines (ϳ50% of the overall intracellular drug fluorescence). Quantitatively, the maximum fluorescence level (MTX-DNA) was nearly 2-fold higher in MCF-7 than in MDA-MB-231 cells. In both cell lines, DHA supplementation did not significantly change the relative contribution of the MTX-DNA complex to the intracellular drug fluorescence.
The MTX level in cytosol (native plus metabolized MTX) was higher in MCF-7 cells (18,890 Ϯ 889 a.u.) than in MDA-MB-231 cells (4452 Ϯ 603 a.u.). In contrast, the proportion of the MTXmetabolite in cytosol was much higher in MDA-MB-231 cells (60.4 Ϯ 6.2%) than in MCF-7 cells (7.7 Ϯ 1.9%). After DHA supplementation, the cytosolic content of MTX increased (to 10,157 Ϯ 768 a.u.) in MDA-MB-231 but not in MCF-7 cells. The proportion of the metabolite increased up to 94.2 Ϯ 2.6% in MDA-MB-231 cells and to 31.6 Ϯ 2.3% in MCF-7 cells. When cells were pretreated for 15 min with the antioxidant NAC, the enhancement of the metabolized MTX fraction by DHA was no longer observed. This indicates that the metabolite may be related to oxidative metabolism of the drug.
The fluorescence level of MTX in a low polarity environment (membranes) was similar in both cell lines (ϳ2600 a.u.). DHA supplementation had no significant effect on the fluorescence levels observed in these compartments.
ROS Levels. The ROS levels were similar in both cell lines (1689 Ϯ 117 a.u./mg of protein in MDA-MB-231 cells and 1663 Ϯ 95 a.u./mg of protein in MCF-7 cells). These levels were not modified either by DHA supplementation or MTX treatment. An 1.3-fold increase ( p Ͻ 0,001) in the ROS level was observed with MTX treatment in DHA-supplemented MDA-MB-231 but not in MCF-7 cells.
Discussion
The above results demonstrate for the first time an association between the chemosensitization of a breast cancer cell line and the cellular distribution and metabolism of an anticancer agent. To achieve this conclusion, we used an experimental system involving two human breast cancer cell lines with a differential sensitivity to several drugs . Cytotoxicity data indicated that, under control conditions, the IC 50 was about 10-fold higher and the overall drug intracellular concentration was 2.5-fold higher in MCF-7 than in MDA-MB-231 cells, showing that the MCF-7 cell line is less at ASPET Journals on July 7, 2017 dmd.aspetjournals.org sensitive to MTX that the MDA-MB-231 cell line. We took advantage of the differential chemosensitivity of the two breast cancer cell lines to examine the contribution of drug subcellular distribution to this phenomenon. Confocal spectral imaging provided the opportunity to address the subcellular distribution of the anticancer drug according to its molecular interaction within cellular compartments.
In agreement with the main mechanism of action of MTX, i.e., inhibition of the nuclear enzyme topoisomerase II, nuclear drug staining (MTX-DNA fraction) was dominant in both cell lines. However, the higher level of MTX-DNA complexes in the less-sensitive MCF-7 cell line suggests that cell sensitivity to MTX is not a direct consequence of the nuclear accumulation of the drug. Indeed, the repartition and metabolism of the drug in the cytosolic compartment were significantly different between the two cell lines. The staining of the cytosolic complex of native MTX was less intense and less homogenous in MDA-MB-231 than in MCF-7 cells. Special attention should be paid to the metabolite fluorescence, as it was particularly intense in MDA-MB-231 cells. As indicated by the CSI maps, the metabolite was mainly concentrated in perinuclear areas rich in membranes. These areas were not assignable to mitochondria, because they were not colocalized with staining of a mitochondrial fluorescent marker, rhodamine 123. The oxidative pathway of this metabolism was indicated by its inhibition after pretreatment of the cells with NAC antioxidant. In view of this finding, the most likely assignment of the organelles responsible for MTX metabolism is endoplasmic reticulum, rich in oxidation phase I enzymes. This hypothesis was supported by colocalization of this metabolite fluorescence with emission of ER-Tracker Green, an endoplasmic reticulum probe.
The observation that MDA-MB-231 but not MCF-7 cells are chemosensitizable by DHA, a peroxidizable polyunsaturated fatty acid, provided the opportunity to examine the involvement of MTX localization or metabolism in chemosensitivity. DHA enhanced the sensitivity of MDA-MB-231 cells to MTX, whereas it had no effect on MCF-7 cells. CSI data showed that DHA increased MTX accumulation in MDA-MB-231 but not in MCF-7 cells. This accumulation occurred in cytosol and was assigned to metabolized MTX, suggesting a role for this metabolism in DHA-enhanced MTX activity. Reska et al. (1986) indicated that MTX and related molecules are easily subject to oxidative enzymatic action., 1986). Enzymatic oxidation of MTX by peroxidase in the presence of hydrogen peroxide led to a cyclic metabolite (Kolodziejczyk et al., 1988; Bruck and Harvey, 2003) . In our study, the observed metabolite had a fluorescence emission maximum at 654 nm, similarly to the one described by Feofanov et al. (1997a) and supposed by these authors to be a cyclic metabolite. However, the fluorescence spectrum does not provide sufficient structural specificity to assign the emission to an exact chemical formula. Identification of the exact metabolite structure should be a subject of further studies using structurally specific analytical techniques such as vibrational spectroscopy, nuclear magnetic resonance, and mass spectrometry. Therefore, we conclude that the metabolite detected in the present study was a fluorescent molecule originating from MTX oxidation within cancer cells. Isolation of the metabolite and identification of its structure would allow evaluation of its direct cytotoxicity. Brück and Harvey (2003) have reported that highly oxidized MTX metabolites form covalent complexes with DNA to inhibit DNA replication enzymes and may contribute to the cytotoxic effects of the drug (Panousis et al., 1995 (Panousis et al., , 1997 . However, we can note that in our conditions, there was no detectable staining of the metabolite in the nucleus. As an alternative to direct nuclear action of the metabolite, we hypothesize that it could contribute to chemosensitivity by influencing the oxidative status of cells. Indeed, it was shown that the peroxidative conversion of MTX is accompanied by formation of free radical species (Kolodziejczyk et al., 1988) . However, in the present study, MTX treatment of both cell lines did not lead to an increase in ROS as measured with CM-H 2 DCFDA. In contrast, ROS levels were increased by MTX in DHA-supplemented MDA-MB-231 cells.
The polyunsaturated fatty acid DHA, with its six double bonds, is very prone to oxidation and therefore provides abundant targets for ROS. We demonstrated previously that DHA supplementation leads to high lipid peroxidation in MDA-MB-231 cells and to moderate lipid peroxidation in MCF-7 cells . This is in accordance with our current observation of a high concentration of an oxidized MTX metabolite in MDA-MB-231 cells and a low concentration of the metabolite in MCF-7 cells. Products of lipid peroxidation such as hydroperoxides and aldehydes have been implicated in cytotoxic process and increase drug efficacy (Das, 2002; Stoll, 2002; Dianzani, 2003) . This might explain why NAC inhibited the DHAinduced enhancement of MTX toxicity in MDA-MB-231 cells. Thus, conditions favoring increased lipid peroxidation in response to MTX would lead to higher activity of the drug. Further studies of enzymes responsible for MTX metabolism should provide complementary knowledge on the different sensitivities of cancer cell lines to antitumor agents, which are necessary for exploration of new therapeutic perspectives.
